GT Biopharma, Inc. (GTBP) Financials

GTBP Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 10.0 million 2.4 million
Dec. 31, 2025 8.1 million 2.3 million
Sept. 30, 2025 4.3 million 1.3 million
June 30, 2025 7.1 million 2.3 million

GTBP Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -2.5 million 46000
Dec. 31, 2025 -4.0 million 432000
Sept. 30, 2025 -3.7 million 379000
June 30, 2025 -3.0 million 7000

GTBP Net Income

No data available :(

GTBP Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 8.9 million - -
Dec. 31, 2025 6.8 million - -
Sept. 30, 2025 2.6 million - -
June 30, 2025 5.2 million - -

GTBP Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 30.3 million
Dec. 31, 2025 5.5 million
Sept. 30, 2025 3.9 million
June 30, 2025 2.8 million

GTBP Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 - 413000 2.4 million -
Dec. 31, 2025 - 1.4 million 4.2 million -
Sept. 30, 2025 - 634000 2.7 million -
June 30, 2025 - 363000 1.2 million -

GTBP Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 - -
Dec. 31, 2025 - -
Sept. 30, 2025 - -
June 30, 2025 - -

GTBP

Price: $0.44

52 week price:
0.26
3.85

Earnings Per Share: -6.46 USD

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 64789

Market Capitalization: 14.3 million

Links: